As chronic hepatitis C virus (HCV) drug development approaches the end-game following the launch of the first pan-genotypic regimen Epclusa ([sofosbuvir + velpatasvir]; Gilead), recent and upcoming advances in chronic hepatitis B virus (HBV) treatment emerged as an important focus of the International Liver Conference (ILC) 2017, the annual meeting of the European Association for the Study of the Liver (EASL), which took place in Amsterdam, the Netherlands, on 19–23 April 2017.

2017 Post-EASL Report summarizes several notable highlights and key abstracts from this year’s EASL conference.

Скачать (PDF, 1.86MB)

Source

Related News

2527

People living with HIV from EECA Call to the international society

2436

Resolution of the Regional Meeting of the Civil Society of the EECA region on Migration and Health – please, sign.

2554

The Oldest Person Living With HIV Turns 100

2471

FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine)

1792

New Manual on Monitoring and Documentation of LGBTQ Human Rights Violations